SUMMARY
INTRODUCTION

62
The Ebola virus disease (EVD) outbreak in west Africa is the largest in history. As of November, 63 2015, over 28 500 EVD cases have been reported with an estimated 15 000 survivors. 1 
64
Community-led survivor networks have alerted health-care providers to a variety of convalescent 65 symptoms, including vision and hearing loss and arthralgia. [2] [3] [4] 
67
Understanding of the nature, timing, and prevalence of EVD sequelae remains limited.5 -13 
68
Disabling sequelae, including ocular, auditory, and arthritic symptoms, have been described in 69 small studies from previous outbreaks. 7, [9] [10] [11] 13 In the current outbreak, one qualitative study of 70 100 survivors in Sierra Leone reported blurred or partial loss of vision in convalescence but did 71 not quantify these sequelae. 2 Surveys of 105 survivors in Guinea 14 and of 81 survivors in Sierra 
Role of Funding Source
148
The research was funded in part by the Canadian Institutes of Health Research. The funder had 149 no role in study design, data collection, data analysis, data interpretation, or writing of the report.
150
The study leads (JGM, MJV) and corresponding author (SM) had full access to all the data in the 151 study and had final responsibility for the decision to submit for publication. 
ACKNOWLEDGEMENTS:
366
We thank the patients in the Port Loko Ebola Survivor Clinic. We acknowledge the coordination Fisher's exact test 4 At anytime during acute EVD illness (before and within Ebola facility, including ETU), self-reported. Fever included history of fever within the 2 days prior to Ebola facility admission or temperature >38.0°C at the time of EVD case-investigation by the surveillance team. Acute EVD symptom data were missing in 32 of 4,155 responses (0.1%).
5
All patients with uveitis had a history of fever during acute EVD 6 A subset of patients had data on cycle-threshold and duration of acute EVD 7
Wilcoxon rank-sum 2-sided test was used because the distribution of the data were skewed 3⋅33 (1⋅87-5⋅91) <0⋅0001 3⋅04 (1⋅87-4⋅94) <0⋅0001 1⋅06 (0⋅68-1⋅66) 0⋅80 0⋅84 (0⋅55-1⋅28) 0⋅41
Duration of acute EVD (N=190) 5, 7 1⋅11 (0⋅84-1⋅46) 0⋅48 1⋅01 (0⋅80-1⋅27) 0⋅93 1⋅00 (0⋅78-1⋅28) 0⋅97 0⋅84 (0⋅67-1⋅05) 0⋅12 EVD (Ebola virus disease). OR (odds ratio). 1 Symptoms began during ETU stay or after discharge; diagnoses include uveitis or conjunctivitis. 2 Symptoms began during ETU stay or after discharge. 3 For every 5-year increase in age 4 At anytime during acute EVD illness (before and within Ebola facility, including ETU), self-reported. Fever included history of fever within the 2 days prior to Ebola facility admission or temperature >38.0°C at the time of EVD case-investigation by the surveillance team. 5 Restricted to subset of the population with cycle threshold values and data on duration of acute EVD. 6 For every 5-point decrease in the cycle threshold value. 7 For every increase in 5 days (from symptom onset to first negative EVD RT-PCR during acute EVD infection).
